ClinicalTrials.gg
Status unknownNCT04729998Updated Jan 29, 2021

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

A Phase 1 interventional study of Rivaroxaban film-coated tablet 20 mg and Xarelto® film-coated tablet 20 mg in Bioequivalence, sponsored by Pharmtechnology LLC. Status unknown at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Pharmtechnology LLC · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is an open-labeled, laboratory-blinded, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Xarelto®, 20 mg film-coated tablets) or the test (Rivaroxaban, 20 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent.

02

Conditions studied

  • Bioequivalence

Keywords

  • Rivaroxaban
  • Bioequivalence
  • Xarelto
03

In context

Lead sponsor

Pharmtechnology LLC is the lead sponsor of 27 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy caucasian men aged between 18 to 45 years;
  2. verified diagnosis "healthy" according to the anamnesis data and the results of standard clinical, laboratory and instrumental examination methods, physical examination and anamnestic examination;
  3. 18.5-30 kg/m²;
  4. the results of an X-ray or fluorographic examination of the chest organs within the normal range (the results of an examination carried out within 12 months before the start of the study may be provided);
  5. consent to use a double barrier method of (condom + spermicide) or complete sexual abstinence, as well as consent not to take part in sperm donation from the moment of taking the drug in the first period, during the entire study and within 14 days after taking the drug in the second period research;
  6. subjects are able to understand the requirements of the study, to sign a written , and also to accept all the restrictions imposed during the course of the study, and to agree to return for the required investigations.

Exclusion criteria

Exclusion Criteria:

  1. burdened allergic history, to rivaroxaban or that are part of any of the drugs, or intolerance to these components;
  2. pathologies of the cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys and blood;
  3. other diseases that, in the opinion of the researcher, may affect the absorption, distribution, metabolism or excretion of both drugs, or increase the risk of negative consequences for the volunteer;
  4. a history of brain or spinal cord injury, recent surgery on the brain, spinal cord or eyes;
  5. history of internal bleeding of any genesis;
  6. a history of coagulation disorders (eg, von Willebrand disease, hemophilia);
  7. hereditary intolerance to lactose or galactose (for example, congenital lactase deficiency or glucose-galactose malabsorption), since the composition of the tested and reference drugs includes lactose monohydrate;
  8. the presence of mental disorders, including a history;
  9. seizures, epilepsy and any other neurological disorders in history;
  10. surgical interventions on the gastrointestinal tract, with the exception of appendectomy;
  11. acute infectious diseases that ended less than 4 weeks before taking the drug in the first period;
  12. dehydration due to diarrhea, vomiting or other reason within the last 24 hours before taking the drug in the first period of the study. Moreover, if vomiting or diarrhea was a manifestation of an infectious disease, then participation in the study is possible only 4 weeks after the last symptom.
  13. Clinically significant abnormalities on the , the level of systolic blood pressure (SBP) measured in the sitting position at the time of screening \<100 mm Hg or ≥ 130 mm Hg and / or diastolic blood pressure (DBP) \<60 mm Hg or ≥ 85 mm Hg;
  14. Heart rate less than 60 beats/min or more than 90 beats/min at the time of screening, respiratory rate less than 12 or more than 18 per minute at the time of screening, body temperature below 36.0 ° C or above 37.0 ° C at the time of screening;
  15. use of any prescription and ATC drugs:

    • including herbs and food additives, vitamins that can have a significant effect on the PK of rivaroxaban or data on the effect of which on the pharmacokinetics of rivaroxaban are unknown, as well as question the characterization of the volunteer as healthy, less than 14 days before taking the drug in the first period;
    • including the use of drugs that are inducers or inhibitors of isoenzymes , CYP2J2 ( protease inhibitors, antifungal drugs of the azole group, clarithromycin, erythromycin, phenytoin, carbamazepine, phenobarbital, St. John's wort preparations, etc.), less than 30 days before taking the drug in the first period;
  16. donation of plasma or blood (450 ml or more) less than 2 months (60 days) before taking the drug in the first period;
  17. consumption of caffeine and xanthine-containing drinks and products (tea, coffee, chocolate, cola, etc.), products containing poppy seeds, less than 48 hours before taking the drug in the first period;
  18. consumption of alcohol and alcohol-containing foods and beverages less than 48 hours before taking the drug in the first period;
  19. use of citrus fruits (including grapefruit and grapefruit juice) and cranberries (including juices, fruit drinks, etc.) less than 7 days before taking the drug in the first period;
  20. intake of more than 10 units alcohol per week (1 unit of alcohol is equivalent to ½ liter of beer, 200 ml dry wine or 50 ml of spirits) or history of alcoholism, drug addiction, drug abuse;
  21. intense physical activity less than 24 hours before taking the drug in the first period;
  22. smoking more than 10 cigarettes per day, including less than 24 hours before taking the drug in each period and during each study period;
  23. participation in other clinical trials of drugs less than 3 months before taking the drug in the first period;
  24. test positive for syphilis, , or HIV at the time of screening;
  25. positive test for alcohol in exhaled air;
  26. positive urinalysis for the content of narcotic and potent substances during screening (opiates, morphine, barbiturates, benzodiazepines, cannabinoids/marijuana);
  27. the value of standard laboratory and instrumental parameters that go beyond the reference values;
  28. lack of intention of volunteers to comply with the Protocol requirements throughout the course of the study and/or lack, in the opinion of the Investigator, of the volunteers' ability to understand and evaluate the information on this study as part of the form signing process, in particular regarding the expected risks and possible discomfort;
  29. tattooing and piercing within 30 days prior to first drug administration;
  30. difficulty swallowing tablets;
  31. difficulty with taking blood (for example, difficult access to the veins).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Other
    Sequence TR

    17 subjects assigned to the sequence TR will receive a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in Period 1 and a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.

    Drug: Rivaroxaban film-coated tablet 20 mg · Drug: Xarelto® film-coated tablet 20 mg

  • Other
    Sequence RT

    17 subjects assigned to the sequence RT will receive a single 20 mg dose of the reference product Xarelto® (1 x 20 mg tablet), marked as R in the sequence, in Period 1 and a single 20 mg dose of the test product Rivaroxaban (1 x 20 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a standardized breakfast. The tablet must be swallowed whole and must not be chewed or broken.

    Drug: Rivaroxaban film-coated tablet 20 mg · Drug: Xarelto® film-coated tablet 20 mg

Interventions

  • Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.

    Also known as: The test product

  • Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.

    Also known as: The reference product

06

What researchers measure

Primary outcomes

  1. Cmax of rivaroxaban in plasma after administration of the test and the reference products.

    Maximum observed concentration in plasma.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

  2. AUC0-t of rivaroxaban in plasma after administration of the test and the reference.

    Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration using the linear trapezoidal method

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

Secondary outcomes

  1. Tmax of rivaroxaban in plasma after administration of the test and the reference products.

    Time of maximum observed concentration; if it occurs at more than one time point, Tmax is defined as the first time point with this value.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

  2. AUC0-INF of rivaroxaban in plasma after administration of the test and the reference products.

    Area under the concentration time curve extrapolated to infinity, calculated as AUC0-t + ĈLQC (the predicted concentration at time TLQC) / λZ (apparent elimination rate constant).

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

  3. Residual area of rivaroxaban in plasma after administration of the test and the reference products.

    Extrapolated area (AUCresid%=100%\*(AUC0-INF - AUC0-t)/AUC0-INF).

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

  4. λZ of rivaroxaban in plasma after administration of the test and the reference products.

    Apparent elimination rate constant.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

  5. Terminal elimination half-life (T1/2) of rivaroxaban in plasma after administration of the test and the reference products.

    Terminal elimination half-life, calculated as ln(2)/λZ.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.67, 1.00, 1.33, 1.67, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 5.30, 6.00, 8.00, 12.00, 16.00, 24.00, 36.00. 48.00 hours after each drug administration.

07

Study locations

1 site
  • Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl"
    Yaroslavl, 150047, Russian Federation
    • Alexander Khokhlov · Contact81079109756777
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2021; primary completion for Feb 2021, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 29, 2021
StartEst.
Jan 30, 2021
Primary completionEst.
Feb 15, 2021
CompletionEst.
Feb 15, 2021
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04729998
Collaborators
ClinPharmInvest, LLC
Responsible party
Sponsor
First posted
Jan 29, 2021
Start date
Jan 30, 2021 (estimated)
Primary completion
Feb 15, 2021 (estimated)
Completion
Feb 15, 2021 (estimated)
Last update
Jan 29, 2021

Study contacts

Veronika Kumpel
Contact
specialist.fs@ft.by
80173094418
Andrei Yaremchuk
Contact
development@ft.by
80291268246
Alexander Khokhlov
principal investigator · ClinPharmInvest, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion